It was notable that IL12B, LIF and S100A12 emerged as potential therapeutic targets for T1D with renal complications, and that FGF19, FGF23, CCL7, TNFSF14 and IL-13 also deserved attention for T2D with renal complications. This evidence concerns the gene FGF23 and type 1 diabetes mellitus.